NAGE Earnings & Financial Statements
Niagen Bioscience Inc
$2.58
+$0.05(+1.98%)
37
Overall
35
Value
18
Tech
60
Quality
Market Cap
$200.19M
Volume
444.19K
52W Range
$2.61 - $7.95
Target Price
$10.10
NAGE earnings and financial statements: Niagen Bioscience Inc's income statement, balance sheet and cash flow statement, annual and quarterly.
NAGE Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $129.42M | $99.60M | $83.57M | $72.05M | $67.45M |
| Cost of revenue | $46.23M | $38.01M | $32.79M | $29.25M | $25.96M |
| Operating income | $16.28M | $7.73M | -$5.60M | -$18.63M | -$27.07M |
| EBITDA | $18.98M | $9.67M | -$3.91M | -$14.66M | $512.0K |
| Net income | $17.38M | $8.55M | -$4.94M | -$16.54M | -$27.13M |
| EPS (diluted) | $0.20 | $0.11 | $-0.07 | $-0.24 | $-0.40 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $106.41M | $68.28M | $54.96M | $54.06M | $57.84M |
| Total liabilities | $29.87M | $22.18M | $26.51M | $25.39M | $26.11M |
| Shareholders’ equity | $76.53M | $46.09M | $28.46M | $28.67M | $31.73M |
| Cash and equivalents | - | - | $27.20M | $20.30M | $28.20M |
| Long-term debt | $1.81M | $1.66M | $2.58M | $3.56M | $4.15M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | $13.50M | $12.11M | $7.12M | -$15.10M | -$24.16M |
| Capital expenditure | - | -$163.0K | -$148.0K | -$334.0K | -$409.0K |
| Free cash flow | $13.50M | $12.11M | $6.97M | -$15.43M | -$24.57M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | NAGE | $2.58 | +2.0% | 444.19K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |